Peak Number	Time [min]	Type	Peak Width(FWH [min]	Area [Intens. * sec]	Height	Description	Start Point		End Point	
							Time[min]	Height	Time[min]	Height
1	21.91	BB	0.0473	101833.53	34459.76		21.85	56	21.99	51
2	23.27	BB	0.1685	7656562.14	724353.37		22.91	336	23.43	25395
3	24.82	BV	0.0404	116360.83	45187.20		24.77	2589	24.87	3629
4	24.91	VB	0.0400	173666.77	68956.47		24.87	3629	24.96	4600
5	25.28	BB	0.0405	129556.19	51005.85		25.23	1019	25.35	760
6	26.16	BV	0.3166	19826989.67	1065966.20		25.63	1464	26.24	10628
7	26.38	VB	0.1161	8384325.97	931228.59		26.24	10628	27.10	23477
8	29.66	BB	0.0381	92273.96	37011.47		29.60	6023	29.74	7223
9	31.03	BB	0.0342	77637.72	33086.16		30.97	6995	31.13	7155
10	33.52	BB	0.1440	5238944.12	348448.68		33.27	7281	33.95	10301

Figure S1: Representative GC chromatogram of tamanu oil components

Figure S2: Graphical representation of % Wound Contraction

Groups	(H& E)	Masson's trichome (MT)
Control		
Tamanu oil		
Murivenna®		
BG1		
BG4		

BG8		

Figure S3: Photomicrographs (100x) showing H&E stain and MT stain section of skin tissues at day 15 for control, standard and formulation treated groups

(**Yellow**- re-epithelialization, **Green**- irregular connective tissue, **Blue**- epidermis, **Black**- collagen formation and **h**- healed area with multiple layers of fibrous connective tissue)

Figure S4: TGF-β type 1 kinase (5E8W) with binding site

Table S1: Molecular docking results (Kcal/mol)

Compounds	Structure	5KF4	3UTZ	3V96	5K5X	6T9D	4D2R	7SZL	2L3Y
Calophyllolide		-4.9	-4.5	-4	-4.4	-4.7	-4.6	-4.8	-4.9
Inophyllum C		-5.8	-3.1	-7	-7.6	-5.4	-7.5	-7.2	-5.6

Calanolide A		-4	-6.7	-4.4	-6.5	-6	-7.2	-7.7	-6.1
Oleic acid		-4.5	-5.9	-4	-5.2	-6.4	-6.5	-6.8	-5.6
Linoleic acid		-5.8	-5.8	-6.2	-7	-7.6	-7.6	-5.8	-7.6

Palmitic acid		-5.8	-4.6	-5.3	-6.6	-7.2	-7.2	-6.1	-6.7
4-Norlanosta-17(20),24-diene-11,16-diol-21-oic acid, 3-oxo-16,21-lactone		-4.9	-6	-4.7	-5.8	-4.8	-6.4	-6.1	-6.9
Hyenic acid		-5.5	-4.9	-4.4	-4.8	-5.1	-4.9	-5	-5.9

Table S2: Molecular properties of Ligands (constituents of Tamanu oil)

Properties/ Drugs	**Molecular Weight**	**LogP**	**No. of Rotatable Bonds**	**No. of H-Bond Acceptors**	**No. of H-Bond Donors**	**Surface Area (m^2)**
Calophyllolide	416.473	5.8017	4	5	0	180.154
Inophyllum C	402.446	5.2439	1	5	0	173.473
Calanolide A	370.445	4.3801	2	5	1	158.144
4-Norlanosta-17(20),24-diene-11,16-diol-21-oic acid, 3-oxo-16,21-lactone	454.651	5.7834	3	4	1	198.78

Table S3: Predicted ADMET properties of compounds

Properties	Calophyllolide	Inophyllum C	Calanolide A	4-Norlanosta-17(20),24-diene-11,16-diol-21-oic acid, 3-oxo-16,21-lactone
Water solubility (log mol/L)	-5.699	-4.952	-4.982	-5.716
Caco2 permeability (log Papp in 10-6 cm/s)	1.121	1.119	0.757	0.605
Skin Permeability (log Kp)	-2.702	-2.729	-3.013	-3.253
P-glycoprotein substrate	No	No	Yes	No
P-glycoprotein I inhibitor	Yes	Yes	Yes	Yes
P-glycoprotein II inhibitor	Yes	Yes	Yes	Yes
VDss (human)(log L/kg)	0.47	0.169	0.371	-0.124
Fraction unbound (human)(Fu)	0.147	0.165	0.103	0
BBB permeability (log BB)	-0.823	-0.453	-0.322	-0.56
CNS permeability (log PS)	-1.678	-1.606	-1.82	-1.59
CYP2D6 substrate	No	No	No	No
CYP3A4 substrate	Yes	Yes	Yes	Yes
CYP1A2 inhibitor	Yes	Yes	Yes	No
CYP2C19 inhibitor	Yes	Yes	Yes	No
CYP2C9 inhibitor	Yes	Yes	Yes	No

CYP2D6 inhibitor	No	No	No	No
CYP3A4 inhibitor	Yes	Yes	Yes	No
Total Clearance(log ml/min/kg)	0.757	0.589	0.506	0.331
Renal OCT2 substrate	No	No	No	No
AMES toxicity	No	No	No	No
Max. tolerated dose (human)(log mg/kg/day)	0.255	0.11	-0.315	-0.535
hERG I inhibitor	No	No	No	No
hERG II inhibitor	Yes	Yes	Yes	No
Hepatotoxicity	No	Yes	No	No
Skin Sensitisation	No	No	No	No

Table S4: Period of epithelialization in all groups

Sl. no.	Groups	Period of Epithelialization (days)
1.	Control	12.83±0.30
2.	Tamanu oil	10.16 ±0.47**
3.	Murivenna®	10.00±0.36**
4.	BG1	11.50±0.42*
5.	BG4	8.16±0.60**
6.	BG8	6.66±0.66**

Data are expressed as Mean ± SEM (n=6) and analysed by one-way ANOVA method of variance followed by Dunnett test for multiple comparison. ns $p>0.05$, * $p<0.05$, ** $p<0.01$, in comparison to control. (Where, ns= non-significant, * moderately significant,

Table S5: Formulation of Bigels

	BG1	**BG2**	**BG3**	**BG4**	**BG5**	**BG6**	**BG7**	**BG8**
OLEOGEL PHASE								
Tween 20 (mL)	3	3	3	3	3	3	3	3
Tamanu oil (mL)	5	10	15	20	5	10	15	20
HYDROGEL PHASE								
Micronized Xanthan gum (g)	1	1	1	1	2	2	2	2
Geogard® ECT (mL)	1	1	1	1	1	1	1	1
Vanilla fragrance oil (mL)	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Water (mL)	q.s 100mL							